GUILFORD, Conn., Mar. 01, 2019 — InveniAI® Corporation, a global leader in pioneering the application of artificial intelligence (AI) and machine learning (ML) to transform innovation across healthcare and other industries, is pleased to announce that the company was featured in The Guardian newspaper's Rare Diseases Campaign on Rare Disease Day. This worldwide event has gained momentum since its inception in 2008 with the main objective of raising awareness on the impact of rare diseases that are more often than not misdiagnosed and mistreated.
According to the National Organization for Rare Disorders (NORD), only 5% of rare diseases have an FDA-approved treatment or therapy. Rare diseases are multifaceted in nature with over 9,000 rare and ultra-rare diseases that span several thousand genes, 3,000+ known molecular-target associations, 1,500+ pathways, and thousands of disease pathophysiologies and symptoms. This presents an ideal opportunity to apply artificial intelligence (AI) and machine learning (ML) to uncover therapeutic insights.
InveniAI's platform, AlphaMeld™, generates testable hypotheses, therapeutic candidates, and insights that can be sorted based on disease severity, gene ontology, disease pathways, proteinopathies, standard of care, emerging innovation, and enabling technologies while factoring in medical, scientific, strategic, and commercial considerations.
InveniAI has leveraged its platform for numerous collaborations such as Alexion, Axcella Health, Centrexion, and Kyowa Hakko Kirin, as well as for internal efforts that have resulted in the identification of a rare disease portfolio.
"While the healthcare industry is making strides to find therapies for rare diseases, we believe that our artificial intelligence and machine learning platform can make a significant impact in helping our partners create breakthrough treatments with a high probability of success," said Krishnan Nandabalan, Ph.D., CEO and President, InveniAI Corporation.